> ## Content Index > Fetch the complete content index at: https://www.theamericanquorum.com/llms.txt > Use this file to discover other available public pages before exploring further. # Pfizer Seeks COVID-19 Vaccine Authorization for Children Under 5 as FDA Sets February Review - URL: https://www.theamericanquorum.com/taq-historical-2022-02-05-healthcare/ - Published: 2022-02-06T04:59:00.000Z - Updated: 2022-02-06T04:59:00.000Z - Description: Pfizer and BioNTech have begun a rolling FDA submission for a 3-microgram COVID-19 vaccine regimen in children 6 months through 4 years as third-dose testing continues. - Author: Kenneth R. Deans Jr. - Tags: Healthcare, #Import 2026-08-31 09:09 Pfizer and BioNTech have begun asking U.S. regulators to authorize their COVID-19 vaccine for children from 6 months through 4 years old, opening a review that could make the youngest Americans eligible for vaccination while a study of a third pediatric dose continues. The companies said Tuesday that they initiated a rolling emergency-use submission at the request of the Food and Drug Administration. The proposed primary regimen uses two 3-microgram doses given three weeks apart, one-tenth of the dose used for people 12 and older. Pfizer’s [announcement](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-initiate-rolling-submission-emergency?ref=theamericanquorum.com) said the companies ultimately expect data on a third dose and are evaluating a three-dose series for the age group. The FDA moved quickly to schedule an advisory committee meeting for February 15, according to the agency’s [meeting announcement](https://www.prnewswire.com/news-releases/coronavirus-covid-19-update-fda-advisory-committee-meeting-to-discuss-request-for-authorization-of-pfizer-biontech-covid-19-vaccine-for-children-6-months-through-4-years-of-age-301473265.html?ref=theamericanquorum.com). The unusual approach could allow regulators to consider the safety and immune-response evidence from two doses while the companies gather additional information on whether a third improves protection. ## The youngest age group is the last major eligibility gap Children under 5 are the only large U.S. age group for whom no COVID-19 vaccine is currently authorized. The gap has become more visible during the Omicron wave, which has produced very high infection levels and disrupted child care, preschool programs and households with young children. The regulatory path follows the expansion of Pfizer’s vaccine to older children. On October 29, the FDA [authorized](https://www.fda.gov/news-events/press-announcements/fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use-children-5-through-11-years-age?ref=theamericanquorum.com) a 10-microgram formulation for children ages 5 through 11 after reviewing trial data on safety and immune response. The Centers for Disease Control and Prevention then [recommended](https://www.cdc.gov/media/releases/2021/s1102-PediatricCOVID-19Vaccine.html?ref=theamericanquorum.com) vaccination for that age group on November 2, launching a program covering roughly 28 million children. For children younger than 5, Pfizer and BioNTech selected an even smaller 3-microgram dose to balance immune response against side effects such as fever. Their trial includes children 6 months through 4 years and evaluates antibody responses relative to those seen in vaccinated young adults. ## Two doses produced a mixed immune-response picture The companies’ December [trial update](https://www.pfizer.com/news/announcements/pfizer-and-biontech-provide-update-ongoing-studies-covid-19-vaccine?ref=theamericanquorum.com) explains why the development program shifted toward a third dose. Two 3-microgram doses produced an immune response in children 6 months through 2 years that met the study’s prespecified standard, but the response in children ages 2 through 4 did not meet that threshold. Rather than increase the individual dose, Pfizer and BioNTech amended the study to evaluate a third 3-microgram shot at least two months after the second. That strategy is intended to preserve the favorable tolerability of the very small dose while determining whether an additional exposure can raise antibody levels sufficiently across the full under-5 population. The rolling submission means the FDA can begin reviewing available manufacturing, safety and immunogenicity information before the full three-dose dataset is complete. Emergency authorization still requires the agency to determine that the known and potential benefits outweigh known and potential risks for the proposed use. ## Omicron raises both urgency and scientific complexity The review is occurring in a markedly different viral environment from the one in which the original vaccine trials were conducted. Omicron can infect people with immunity from vaccination or prior infection more readily than earlier variants, although vaccination continues to provide important protection against severe disease. A contemporaneous [JAMA study](https://jamanetwork.com/journals/jama/fullarticle/2788485?ref=theamericanquorum.com) examining symptomatic disease during Omicron circulation found materially stronger protection after three mRNA doses than after two among adults. The pediatric trial is not directly comparable, but the broader evidence helps explain why regulators and manufacturers are increasingly focused on dose number and timing rather than simply extending an unchanged schedule to younger ages. Young children generally face lower absolute risk of severe COVID-19 than older adults, but low risk is not zero risk. Pediatric hospitalizations have risen during periods of intense community transmission, and young children can also transmit infection within households. Regulators therefore must weigh the direct health benefit to the child alongside the uncertainty surrounding a newly tailored dose and evolving variants. ## A February decision could reshape family protection If the FDA authorizes the vaccine after its February review, the CDC would still need to make recommendations on how it should be used in practice. Providers would then face the logistical task of delivering a 3-microgram pediatric formulation to infants and preschool-age children, many of whom receive routine immunizations through pediatric offices rather than mass vaccination sites. The experience with the 5-to-11 program offers a model for distribution but also shows that authorization does not guarantee rapid uptake. Parents weigh disease risk, vaccine safety, school and child-care disruption, prior infection and advice from pediatric clinicians. Those considerations may be even more pronounced for infants and toddlers. For now, the FDA is preparing to review a two-dose request while the companies continue collecting third-dose data. That creates a regulatory question without a direct precedent in the U.S. COVID-19 vaccination campaign: whether the available evidence justifies beginning protection for the youngest children before the manufacturer has completed the regimen it believes may ultimately provide the most robust response.